Researchers have pulled a paper about a drug used to treat pancreatic tumors due to “statistical errors.”
The 2014 paper suggested a drug that appears to treat pancreatic tumors also works in Chinese patients. We’re not exactly sure what went wrong with “A randomized phase II study of everolimus for advanced pancreatic neuroendocrine tumors in Chinese patients,” however, because the retraction note is not particularly helpful. Here’s the whole thing, published in Medical Oncology:
This article has been retracted by the authors because the authors discovered statistical errors which need further validation.
The paper has been cited only by the retraction note, according to Thomson Scientific’s Web of Knowledge.
We sent an email to the corresponding author Li-Sheng Wang at the Shenzhen Municipal People’s Hospital, and to the editor in chief of the journal. We’ll update if we hear back. An email to the other corresponding author, Lei Liu at the Shenzhen Children’s Hospital, bounced back.
Hat tip: Rolf Degen
Like Retraction Watch? Consider making a tax-deductible contribution to support our growth. You can also follow us on Twitter, like us on Facebook, add us to your RSS reader, and sign up on our homepage for an email every time there’s a new post. Click here to review our Comments Policy.